Twist's 23% Growth Beat Didn't Save the Stock: Q3 Shows the Profitability Test Starts Now

The stock reaction put the profitability test front and center

Twist Bioscience again beat revenue expectations, but the market focused on the path to profitability. Fiscal Q3 delivered revenue of $118.4 million, ahead of consensus, while adjusted EPS came in at a $0.56 loss versus the expected $0.48 loss. The stock's 7.7% premarket drop to $84.50 made the message clear: investors still see room for growth, but they now want stronger proof that Twist can convert that growth into earnings progress. Bulls can still point to raised fiscal 2026 revenue guidance and management's expectation of adjusted EBITDA breakeven in the fourth quarter. Bears, though, are focused on the simpler takeaway: growth alone no longer insulated the shares from a disappointment on earnings.

Why the last quarter matters more than the beat

The core debate is no longer whether Twist has a credible growth story. It does. The question is whether the market will keep rewarding top-line momentum before the profitability turn shows up in reported results. That is why the final quarter matters so much: investors will be watching whether management can translate growth into margin progress and meet its breakeven target. If it does, this report may look like a reset that lowered expectations at the right time. If not, the market may treat future growth headlines less favorably.

Q3 improved the business model, not just the headline growth rate

The main upgrade in this quarter was not only that Twist grew. It was that the growth looked easier to monetize.

Higher gross margin matters more than a revenue beat alone

In fiscal Q3, revenue rose 23% year over year, but the more important development was margin improvement. Gross margin expanded to 52.8%, and 70% of incremental revenue flowed to gross margin. That is a better signal than a top-line beat driven mainly by discounting or lower-value mix. In simple terms, each additional sales dollar left more value behind.

Twist has also been making its manufacturing process more efficient. Over the past three years, it reported a 60% reduction in manufacturing costs and a 73% improvement in turnaround time. Those operating gains help explain why the quarter's margin expansion mattered: they suggest the company is becoming better at turning demand into throughput and profit.

The mix is shifting toward more recurring demand

Repeat demand is where growth becomes more valuable. Twist's segment breakdown supports that view. DNA Synthesis and Protein Solutions revenue rose 39%, while NGS Applications revenue increased 12%. More importantly, therapeutic revenue grew 49%. That mix matters because therapeutics and core synthesis demand tends to be more recurring than one-off project work.

The same pattern shows up in academic and government revenue, which rose 32% year over year and 21% sequentially. Management attributed that rebound to strength in U.S. accounts and the return of several large customers. For investors, that is an important detail: a growth story is more durable when it is driven by repeat buyers rather than one-quarter spikes.

Adjusted EBITDA breakeven is now the real scoreboard

Twist still posted an adjusted EBITDA loss of $11.3 million, but management said the wider loss reflected planned one-time investments rather than a loss of cost control. If higher-margin repeat work continues to gain share, the fourth quarter does not require extraordinary revenue growth to work. It mainly needs the same mix discipline and operating leverage the company highlighted in Q3.

Management is guiding to roughly 25% year-over-year growth in fourth-quarter revenue and still expects adjusted EBITDA breakeven in the quarter. If that happens, investors will have stronger evidence that Twist is not only growing faster, but also converting extra revenue into profit more effectively.

The final quarter has to turn a good report into a credible earnings turn

Twist has one quarter left in fiscal 2026 to turn a strong third quarter into a believable profit turnaround.

The market's standard remains straightforward: revenue beats attract attention, but profitability delivers relief. Last quarter, Twist delivered revenue above Wall Street's estimate with broad-based execution, yet the stock still fell 7.7% in premarket trading to $84.50 after adjusted earnings came in at a loss of $0.56 a share. Now the burden of proof has shifted. For fiscal Q4, management is guiding to $123 million to $124 million in revenue and still expects adjusted EBITDA breakeven this quarter. That is the milestone investors need to see validated.

What would strengthen or weaken the case

Bulls have a simple argument: Twist is still growing while moving closer to breakeven, and management has said that milestone is the foundation for disciplined, profitable growth. If that trajectory holds, this quarter may prove to be the reset that cleared out skeptics.

Bears will argue that hope is not enough. As long as the company is still losing money, even a small slippage in spending or pricing can look more like a delay than discipline. So the real question is not whether Twist can sell more. It is whether the final quarter can show that each additional sale is producing better operating leverage.

The watch list for investors

The most direct test is simple: miss the Q4 revenue guide or fail to reach adjusted EBITDA breakeven, and the turnaround narrative loses credibility quickly. The window is narrow, which is exactly why this quarter matters now.